



12th November, 2020

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Corporate Relationship Department
The BSE Ltd.
Dalal Street, Fort
Mumbai 400 001.

Manager – Listing
M/s. National Stock Exchange of India Ltd.
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2020 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) along with Limited Review Report of the Statutory Auditors. Please find enclosed a copy of the same for your information.

2. Declaration of second interim dividend of Rs.3 (Rupees three only) per equity share of Rs.2/- each for the financial year 2020-21. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend **i.e. Record date is fixed for 25th November, 2020.**

Payment of the said interim dividend will start from 2nd December, 2020.

3. Dr. Mrs. Leela Digumarti, Independent Director of the Company has been appointed as member of Corporate Social Responsibility Committee and Compensation Committee.


We are also updating the financial results on the website of the Company.

Meeting commenced at 12.00 noon and concluded at 13.35 p.m.

Please find enclosed press release for your information.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited


M. Adinarayana

Company Secretary &
V.P.(Legal & Corp. Affairs)

Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

PR/10/2020-2021

Press Release

NATCO records INR 827.90 Crore consolidated revenue and INR 203.90 Crore of profit, after tax, for the Second Quarter, FY2020-21

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 827.90 Crore for the Second quarter ended on 30th September, 2020, as against INR 518.90 Crore for the same period last year, reflecting 59.5% growth. The net profit for the period, on a consolidated basis, was INR 203.90 Crores as against INR 117.7 Crore same period last year, showing a growth of 73.2%.

Segmental Revenue Split (approx.), as below (All Figures in INR Crore)-

Segment	Revenue, Q2 FY21
API	199.7
Formulations, Domestic	108.3
Formulations, Exports (incl. Profit Share & Foreign Subs)	482.0
Other Operating income	10.7
Other Income	27.2

The Board of Directors has recommended a second interim dividend of INR 3.0 per equity share of INR 2.0 each, for FY 2020-21.

Forwarded for favour of publication
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)